Dr Claude Nicaise has joined Barcelona, Spain-based Minoryx Therapeutics as an independent board member.
He brings over 30 years of regulatory strategy expertise to the orphan diseases specialist, and currently also serves as a board member at Sarepta Therapeutics.
Dr Nicaise founded Clinical Regulatory Services, a biotech-focused advisory service, in 2014, having previously served as senior vice president of strategic development and global regulatory affairs at Alexion Pharmaceuticals from 2008.
Prior to this, Dr Nicaise was vice president of development at Bristol-Myers Squibb, having held a series of regulatory and project leadership positions since joining as director of clinical cancer research in 1984.
Khalid Islam, chairman of the board at Minoryx Therapeutics, said: “We are delighted to have Dr Nicaise join us as an independent board member.
“Claude’s perspective, based on his distinguished career and leadership roles in R&D organisations, will be very valuable to the board as the company continues its on-going evolution.”